Guidelines for Potassium Channel Blocker Use.
This article summarizes recommendations for the clinical use of antiarrhythmic drugs for the treatment and prevention of atrial and ventricular arrhythmias based on current guideline and consensus documents. The choice of antiarrhythmic drug is based on the efficacy and safety profile and influenced by the presence or absence of structural heart disease. Because of its adverse side-effect profile, amiodarone is recommended for the management of atrial fibrillation only when other agents have failed or are contraindicated. For treatment of symptomatic ventricular arrhythmias in the setting of structural heart disease, amiodarone is generally the preferred agent.
Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, 3280 Hospital Drive Northwest, Calgary, Alberta T2N 4Z6, Canada. Electronic address: amgillis@ucalgary.ca.
Anne M
AM
Gillis
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D006801:Humans; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers
Atrial fibrillation; Atrial flutter; Potassium channel blockers; Practice guidelines; Ventricular arrhythmias